Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of…
<!-- Name:DistributionId Value:8831532 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
Browsing Tag
ARDS
Veru Announces Preclinical Results from Expanded Sabizabulin Program into Influenza-Induced Severe…
<!-- Name:DistributionId Value:8801302 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
Veru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized…
<!-- Name:DistributionId Value:8780823 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
BioAegis Therapeutics Announces FDA Clearance of IND for its ‘Inflammation Regulator Protein,’…
NORTH BRUNSWICK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma gelsolin, a highly conserved and…
Veru Submits Emergency Use Authorization (EUA) Application to U.S. FDA for Sabizabulin, its Novel,…
-- The EUA Submission Follows Positive Phase 3 COVID-19 Clinical Trial in which Sabizabulin Demonstrated a 55.2% Reduction in Death in Hospitalized COVID-19 Patients -- -- The Company is in Discussions with Other Regulatory Agencies…
Pharmazz Inc. announces FDA clearance of an IND application for a Phase II clinical trial of…
WILLOWBROOK, Ill., March 10, 2022 (GLOBE NEWSWIRE) -- Pharmazz (“Pharmazz”), Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, today announced U.S. Food and…
Nirsevimab Prophylaxis Wards Off RSV Infections in Healthy Infants
Healthy infants who received a single prophylactic nirsevimab injection leading up to the respiratory syncytial virus (RSV) season were protected…
Heart Failure Patients Still Undertested for CAD
People with new-onset heart failure (HF) continued to lack adequate testing for coronary artery disease (CAD), a common and treatable cause of HF,…
Some Beta Blockers Tied to Lower Recurrence Risk After Prostatectomy
Use of nonselective beta-blockers (nsBBs) at the time of radical prostatectomy may reduce the risk of prostate cancer recurrence, according to a…
BioAegis’ Novel Host-directed Human Protein for Inflammatory Diseases Geared for Growth in 2022
NORTH BRUNSWICK, N.J., Jan. 24, 2022 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage, private company developing therapies for infectious, inflammatory and degenerative diseases based on a portfolio built around gelsolin…